Giant cell and Takayasu arteritis

Current Opinion in Rheumatology

Volumn 19, Issue 1, 2007, Pages 39-43

  Seko, Yoshinori ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Antitumor necrosis factor ; Giant cell arteritis; Magnetic resonance imaging; Positron emission tomography; Takayasu arteritis

Indexed keywords

ACETYLSALICYLIC ACID; CORTICOSTEROID; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; I KAPPA B; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LOW MOLECULAR WEIGHT HEPARIN; MINOCYCLINE; NITRIC OXIDE SYNTHASE; SILDENAFIL; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

AORTA ARCH SYNDROME; AORTA WALL; CLINICAL FEATURE; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GIANT CELL ARTERITIS; HUMAN; IMAGE ANALYSIS; IMAGE ENHANCEMENT; IMAGE QUALITY; MAGNETIC RESONANCE ANGIOGRAPHY; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROMOTER REGION; REVIEW;

ANTIBODIES, MONOCLONAL; CHEMOKINE CCL2; ENZYME INHIBITORS; HUMANS; MAGNETIC RESONANCE ANGIOGRAPHY; MATRIX METALLOPROTEINASES; MINOCYCLINE; RANTES; TAKAYASU'S ARTERITIS; TEMPORAL ARTERITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33845351808     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOR.0b013e3280119866     Document Type: Review

References (40)

1. Gonzarez-Gay MA, Barros S, Lopez-Diaz MJ, et al. Giant cell arteritis. Disease patterns of clinical presentation in a series of 240 patients. Medicine 2005; 84:269-276.
2. Gonzarez-Gay MA, Lopez-Diaz MJ, Barros S, et al. Giant cell arteritis. Laboratory tests at the time of diagnosis in a series of 240 patients. Medicine 2005; 84:277-290.
3. Seyahi E, Ugurlu S, Cumali R, et al. Atherosclerosis in Takayasu arteritis. Ann Rheum Dis 2006; 65:1202-1207.
4. Arnaud L, Kahn JE, Girszyn N, et al. Takayasu's arteritis: An update on physiopathology. Eur J Intern Med 2006; 17:241-246.
5. Gonzalez-Juanatey C, Llorca J, Garcia-Porrua C, et al. Steroid therapy improves endothelial function in patients with biopsy-proven giant cell arteritis. J Rheumatol 2006; 33:74-78.
6. Drigo I, Saccari A, Bacchin C, et al. Glucocorticoid resistance in a girl with Takayasu's arteritis. Ann Rheum Dis 2006; 65:689-690.
7. Desai MY, Stone JH, Foo TKF, et al. Delayed contrast-enhanced MRI of the aortic wall in Takayasu's arteritis: Initial experience. Am J Roentgenol 2005; 184:1427-1431. This study offers a useful imaging technique to detect inflammation in the arterial wall for monitoring disease activity in Takayasu arteritis.
8. Bley TA, Markl M, Wieben O, et al. Inflammatory hyperenhancement persisits in delayed high-resolution MRI in giant cell arteritis. Am J Roentgenol 2006; 186:1197-1198.
9. Bley TA, Wieben O, Uhl M, et al. Assessment of the cranial involvement pattern of giant cell arteritis with 3T magnetic resonance imaging. Arthritis Rheum 2005; 52:2470-2477.
10. Bley TA, Uhl M, Venhoff N, et al. 3-T MRI reveals cranial and thoracic inflammatory changes in giant cell arteritis. Clin Rheumatol 2006 Apr 25 [Epub ahead of print].
11. Bley TA, Wieben O, Uhl M, et al. Integrated head-thoracic vascular MRI at 3T: Assessment of cranial, cervical and thoracic involvement of giant cell arteritis. MAGNA 2005; 18:193-200.
12. Loeb JM, Engelstad B, Creek W. Giant cell arteritis revealed by positron emission tomography. Arthritis Rheum 2006; 54:1710.
13. 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: A prospective study of 35 patients. Arthritis Rheum 2006; 55:131-137.
14. 18F-FDG PET coregistered with enhanced CT. J Nucl Med 2005; 46:917-922.
15. 18F-FDG PET. Nucl Med Commun 2006; 27:547-549.
16. Uthman I, Kanj N, Atweh S. Infliximab as monotherapy in giant cell arteritis. Clin Rheumatol 2005; 25:109-110.
17. Rossa AD, Tavoni A, Merlini G, et al. Two Takayasu arteritis patients successfully treated with infliximab: a potential disease-modifying agent? Rheumatology 2005; 44:1074-1075.
18. Tanaka F, Kawakami A, Iwanaga N, et al. Infliximab is effective for Takayasu arteritis refractory to glucocorticoid and methotrexate. Intern Med 2006; 45:313-316.
19. Matsuyama A, Sakai N, Ishigami M, et al. Minocycline for the treatment of Takayasu arteritis. Ann Intern Med 2005; 143:394-395.
20. Uthman IW, Chaaban H. The use of sildenafil in pediatric Takayasu arteritis. Clin Rheumatol 2006; 25:550.
21. ter Borg EJ, Haanen HCM, Seldenrijk CA. Relationship between histological subtypes and clinical characterics at presentation and outcome in biopsy-proven temporal arteritis. Identification of a relatively benign subgroup. Clin Rheumatol 2006 Jul 1 [Epub ahead of print].
22. Rodriguez-Pla A, Stone JH. Vasculitis and systemic infections. Curr Opin Rheumatol 2006; 18:39-47.
23. Chauhan SK, Tripathy NK, Nityanand S. Antigenic targets and pathogenicity of antiaortic endothelial cell antibodies in Takayasu arteritis. Arthritis Rheum 2006; 54:2326-2333. This study provides evidence that circulating antiaortic endothelial cell antibodies (AAECAs) play a pathogenic role in Takayasu arteritis.
24. Verma DK, Tripathy NK, Verma NS, Tiwari S. Interleukin 12 in Takayasu's arteritis: Plasma concentrations and relationship with disease activity. J Rheumatol 2005; 32:2361-2363.
25. Park MC, Lee SW, Park YB, Lee SK. Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. Rheumatology 2006; 45:545-548.
26. Tripathy NK, Gupta PC, Nityanand S. High TNF-a and low IL-2 producing T cells characterize active disease in Takayasu's arteritis. Clin Immunol 2006; 118:154-158.
27. Chauhan SK, Tripathy NK, Sinha N, Nityanand S. T-cell receptor repertoire of circulating gamma delta T-cells in Takayasu's arteritis. Clin Immunol 2006; 118:243-249.
28. Cid MC, Hoffman MP, Hernandez-Rodriguez J, et al. Association between increased CCL2(MCP-1) expression in lesions and persistence of disease activity in giant-cell arteritis. Rheumatology (Oxford) 2006 Apr 18 [Epub ahead of print].
29. Dhawan V, Mahajan N, Jain S. Role of C-C chemokines in Takayasu's arteritis disease. Int J Cardiol 2006; 112:105-111.
30. Chirinos JA, Corrales VF, Lichtstein DM. ANCA-associated large vessel compromise. Clin Rheumatol 2005; 25:111-112.
31. Becker H, Maaser C, Mickholz E, et al. Relationship between serum levels of macrophage migration inhibitory factor and the activity of antineutrophil cytoplasmic antibody-associated vasculitides. Clin Rheumatol 2006; 25:368-372.
32. Salvarani C, Casali B, Farnetti E, et al. Interleukin-6 promoter polymorphism at position -174 in giant cell arteritis. J Rheumatol 2005; 32:2173-2177.
33. Gonzalez-Gay MA, Oliver J, Sanchez E, et al. Association of a functional inducible nitric oxide synthase promoter variant with susceptibility to biopsyproven giant cell arteritis. J Rheumatol 2005; 32:2178-2182.
34. Gonzalez-Gay MA, Oliver J, Orozco G, et al. Lack of association of a functional single nucleotide polymorphism of PTPN22, encoding lymphoid protein phosphatase, with susceptibility to biopsy-proven giant cell arteritis. J Rheumatol 2005; 32:1510-1512.
35. Martin J, Perez-Armengol C, Miranda-Filloy JA, et al. Lack of association of a functional -94ins/delATTG NFKB1 promoter polymorphism with susceptibility and clinical expression of biopsy-proven giant cell arteritis in Northwest Spain. J Rheumatol 2006; 33:285-288.
36. Shibata H, Yasunami M, Obuchi N, et al. Direct determination of single nucleotide polymorphism haplotype of NFKBIL1 promoter polymorphism by DNA conformation analysis and its application to association study of chronic inflammatory diseases. Hum Immunol 2006; 67:363-373.
37. Rueda B, Lopez-Nevot MA, Lopez-Diaz MJ, et al. A functional variant of vascular endothelial growth factor is associated with severe ischemic complications in giant cell arteritis. J Rheumatol 2005; 32:1737-1741.
38. Jishi AA, Krishman PR, Almawi WY. Takayasu arteritis with high titer of antiphospholipid antibodies and MTHFR polymorphism. J Thromb Thrombolysis 2005; 20:47-50.
39. Morovic-Vergles J. Takayasu's arteritis associated with antiphospholipid antibodies. Rheumatol Int 2006; 26:773-774.
40. Das R, Garewal G, Shaji RV, et al. Investigation of persistent hypochromic microcytosis unmasks hemoglobin Evanston [α 14 (A12) Try→Arg] in a patient of cyclic thrombocytopenia preceding Takayasu's disease. Hematology 2005; 10:427-429.